Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person13
Pyxis Oncology, Inc.
Company
CG Oncology, Inc.
Company
Aktis Oncology, Inc.
Company
Kura Oncology, Inc.
Company
CITIUS ONCOLOGY, INC.
Company
Coherus Oncology, Inc.
Company
Cardiff Oncology, Inc.
Company
Starling Oncology, Inc.
Company
CHAMPIONS ONCOLOGY, INC.
Company
ALX ONCOLOGY HOLDINGS INC
Company
Prologis, Inc.
Company
Onconetix, Inc.
Company
BridgeBio Oncology Therapeutics, Inc.
Company
Primary record15
Pyxis Oncology, Inc. filed 4
SEC form 4 filed by Pyxis Oncology, Inc. (CIK 1782223) on 2026-11-06.
Pyxis Oncology, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On November 5, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and prov
Pyxis Oncology, Inc. filed SCHEDULE 13G/A
0001390202-26-000019.txt : 20261103 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001390202 XXXXXXXX LIVE 3 Common Stock, par value $0.001 per share 09/30/2026 0001782223 Pyxis Oncology, Inc. 747324101 321 Harri
Pyxis Oncology, Inc. filed DEF 14A
SEC form DEF 14A filed by Pyxis Oncology, Inc. (CIK 1782223) on 2026-10-21.
Pyxis Oncology, Inc. filed SCHEDULE 13G/A
on October 2, 2026. GordonMD Global Investments LP 9460 WILSHIRE BLVD, SUITE 420, BEVERLY HILLS, CA, 90212 GordonMD Long Biased Master Fund LP 9460 WILSHIRE BLVD, SUITE 420, BEVERLY HILLS, CA, 90212 GordonMD Long Biased
Pyxis Oncology, Inc. filed SCHEDULE 13G
0001104659-26-113597.txt : 20261005 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0002068530 XXXXXXXX LIVE Common Stock, par value $0.001 per share 10/01/2026 0001782223 Pyxis Oncology, Inc. 747324101 321 Harrison Av
Pyxis Oncology, Inc. filed SCHEDULE 13G/A
, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that i
Pyxis Oncology, Inc. filed 4
SEC form 4 filed by Pyxis Oncology, Inc. (CIK 1782223) on 2026-10-02.
Pyxis Oncology, Inc. filed 8-K
Item 1.01. Entry Into a Material Definitive Agreement. On September 29, 2026, Pyxis Oncology, Inc. (the Company ) entered into an underwriting agreement (the Underwriting Agreement ) with Leerink Partners LLC, Guggenheim
Pyxis Oncology, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 9, 2026, Pyxis Oncology, Inc. (the “Company”) provided a corporate update and issued a press release announcing updated data from its ongoing global Phase 1 monotherapy st
Pyxis Oncology, Inc. filed 4
SEC form 4 filed by Pyxis Oncology, Inc. (CIK 1782223) on 2026-09-08.
Pyxis Oncology, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Executive Officer and Related Compensatio
Pyxis Oncology, Inc. filed 4
SEC form 4 filed by Pyxis Oncology, Inc. (CIK 1782223) on 2026-08-20.
Pyxis Oncology, Inc. filed 4
SEC form 4 filed by Pyxis Oncology, Inc. (CIK 1782223) on 2026-08-14.
Pyxis Oncology, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On August 13, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and provided a